Ascentage Pharma Group Inc.

Ascentage Pharma is an integrated global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs. Its clinical candidates include novel Bcl-2 and Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. The company reports eleven completed or ongoing international registrational trials, including two that are FDA-regulated. Its lead assets are olverembatinib and lisaftoclax.

Ascentage Pharma is an integrated global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs. For more than two decades, its founders and team have leveraged their deep expertise to develop a proprietary drug discovery platform to pursue particularly challenging targets. The company states it is the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators that restore programmed cell death. Its first lead asset, olverembatinib, is described as the first and only third generation BCR-ABL1 TKI approved in China for treatment of patients with CML. The company reports eleven completed or ongoing U.S. and/or international registrational trials, including two that are FDA-regulated.

A leader in the discovery and development of first- and best-in-class small molecule cancer therapies; the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators.

• Olverembatinib (HQP1351)

  Treatment resistant cancers; BCR-ABL/KIT kinase inhibitor; first and only third generation BCR-ABL1 TKI approved in China for treatment of patients with CML.

• Lisaftoclax (APG-2575)

  Leukemias & additional blood cancers; BCL-2 inhibitor.

• Pelcitoclax (APG-1252)

  Solid tumors & blood cancers; BCL-2/XL inhibitor.

• Alrizomadlin (APG-115)

  Solid tumors & blood cancers; MDM2-P53 pathway.

1. 1A Leader in the Discovery and Development of First- and Best-in-class Small Molecule Cancer Therapies -ascentage.com
2. 2About Us -ascentage.com
3. 3Contact Us -ascentage.com
4. 4Ascentage Pharma Group Inc. (United States)wikidata.org